NCT02617277 2026-03-04
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute